Giant-cell arteritis

Curr Opin Ophthalmol. 2008 Nov;19(6):454-60. doi: 10.1097/ICU.0b013e328310da01.

Abstract

Purpose of review: Giant-cell arteritis frequently poses diagnostic and therapeutic challenges. This article summarizes recent investigations concerning diagnosis and treatment of giant-cell arteritis.

Recent findings: Efforts to improve diagnostic accuracy have centered on serologic markers and imaging techniques. Although the erythrocyte-sedimentation rate, C-reactive protein, and platelet count continue to be the primary markers, others such as interleukin-6 and fibrinogen can provide additional information. High-resolution magnetic resonance imaging and angiography, fluorine-18-fluorodeoxyglucose positron emission tomography, and color Doppler ultrasonography can show findings relevant to the diagnosis of giant-cell arteritis. Recent inquiries suggest a steroid-sparing benefit from initiation of treatment with intravenous steroids. Adjunctive treatment with methotrexate may also provide this benefit. Aspirin appears to decrease likelihood of stroke or visual loss in giant-cell arteritis without increasing bleeding complications.

Summary: An expanded repertoire of imaging techniques and serologic markers may supply information relevant to the diagnosis of challenging cases of giant-cell arteritis. Treatment modifications, including initiation with intravenous steroids, or addition of methotrexate or aspirin to the regimen, may decrease morbidity from disease, corticosteroid treatment or both.

Publication types

  • Review

MeSH terms

  • Aspirin / therapeutic use
  • Blood Sedimentation
  • C-Reactive Protein / analysis
  • Fibrinogen / analysis
  • Fluorodeoxyglucose F18
  • Giant Cell Arteritis / diagnosis*
  • Giant Cell Arteritis / drug therapy*
  • Giant Cell Arteritis / etiology
  • Glucocorticoids / therapeutic use
  • Humans
  • Interleukin-6 / blood
  • Magnetic Resonance Angiography
  • Methotrexate / therapeutic use
  • Platelet Count
  • Radiopharmaceuticals
  • Ultrasonography, Doppler, Color

Substances

  • Glucocorticoids
  • Interleukin-6
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Fibrinogen
  • C-Reactive Protein
  • Aspirin
  • Methotrexate